Purpose To evaluate the association between statins and breast cancer stage and mortality in the Women's Health Initiative.
Introduction
Statins are the most widely prescribed cholesterol-lowering drugs with approximately 25 % of US adults using statins in 2008 [1] . Statins are effective in preventing cardiovascular disease by lowering overall cholesterol levels [2] but have also been postulated to lower the risk of cardiovascular disease, stroke and cancer through cholesterol-independent mechanisms [3] [4] [5] .
Statins act primarily as a competitive inhibitor of hydroxyl methyl glutaryl coenzyme A (HMG-CoA) reductase. Additionally, preclinical studies have identified antiproliferative effects [6] , apoptotic [7] [8] [9] and anti-invasive properties. While early observational studies reported associations between statin use and lower breast cancer risk overall [10] [11] [12] , a more recent analysis of data from the Women's Health Initiative (WHI) found no consistent association [13] . Nonetheless, other analyses of the relationship between statins and breast cancer progression suggest that statins may be associated with earlier stage of disease at diagnosis [14] , lower rates of recurrence [15] [16] [17] [18] and lower breast cancer mortality [18, 19] . The purpose of the current analysis is to further address these questions using the extensive follow-up and outcome data available from the WHI. Based on findings in the epidemiologic literature, we predicted that prior statins would result in earlier stage at diagnosis, resulting in reduced morbidity of treatment associated with higher stage and as well as lower mortality rates.
Methods

Study population
The WHI includes an observational study (n = 93,676) and clinical trials (n = 68,132) of hormone therapy (estrogen alone or estrogen ? progesterone), dietary modification (DM), and/or calcium and vitamin D supplementation in postmenopausal women of many races and ethnicities [20] [21] [22] . The current analysis included women enrolled in the observational study and clinical trial components of the WHI. Note that some study participants had less access to the medical care system, which might lead to a lower likelihood of receiving statins and/or a diagnosis of breast cancer at an earlier stage. We therefore excluded from the analysis women who did not report a mammogram within 5 years of study entry (16, 687) , those without health insurance (5, 732) and women with no reported medical care provider (5, 818) . We also excluded 4,239 women with a prior history of breast cancer, 431 women with missing or no information on follow-up, 225 women with incident breast cancer who had missing information on cancer stage, and one with missing information on baseline statin use. The final analysis cohort consisted of 128,675 women.
Statin exposure
Baseline statin exposure was analyzed from both clinical trials and observational study participants, and information on statin intake was collected at years 1, 3, 6 and 9 in the clinical trials, and year 3 in the observational study [20] [21] [22] . Participants were requested to bring all of their current prescription medications to their clinic visit, and report duration of medication use at the first screening interview as well as each follow-up period. Each medication name, but not the dose, was directly entered into the WHI database, which assigned drug codes using Medispan software (First DataBank, Inc., San Bruno, CA) [20] [21] [22] .
Statin use was defined as any HMG-CoA reductase inhibitor used at baseline or during participation in the WHI prior to diagnosis of breast cancer. Statins were further classified based on solubility in octanol as lipophilic or hydrophilic, and also by potency. Lipophilicity may modify the penetration of statins across cellular and mitochondrial membranes. Lovastatin, simvastatin, atorvastatin and fluvastatin are all lipophilic statins, whereas pravastatin is a hydrophilic statin. Fluvastatin and lovastatin are lowpotency statins, pravastatin is a medium-potency statin, and simvastatin and atorvastatin are high-potency statins [23, 24] . Updated information on statin use collected at subsequent participant visits were used to measure statin use as a time-dependent exposure. The newer statins, rosuvastatin and pitavastatin, were not used in the early years of the WHI and are, therefore, not included in this analysis.
Outcomes
Updates on breast cancer diagnoses were reported semiannually in the clinical trials and annually in the observational study, and were confirmed by trained physician adjudicators after review of medical records using the Surveillance Epidemiology and End Results (SEER) coding system [25] . There were 7,883 centrally adjudicated and SEER-coded breast cancer cases [1,477 in situ (19 %), 4,831 localized stage (61 %), 1,499 regional stage (19 %) and 76 distant stage (1 %)] that were diagnosed from the start of the study through 30 September 2010, which was the end of the first WHI Extension Study for a total of 11.5 (SD 3.7) years of follow-up. For the purposes of this analysis, stage was stratified into early (in situ and local)-versus late (regional and distant)-stage disease. Cause of death, including breast cancer-specific mortality, was based on medical record review at the Clinical Coordinating Center. Estrogen receptor (ER) status was classified as ER positive (5,571) versus ER negative (1,039) or borderline [12] . For analyses that included ER status, 1,261 women with breast cancer with unknown or missing ER status were excluded.
Covariates Table 1 lists the potentially confounding or modifying variables collected at baseline entry into the study [20] [21] [22] . These included socio-demographic and medical history variables that could have an impact on whether or not study participants were prescribed statins as well as breast cancer stage at diagnosis and/or breast cancer-specific mortality and other well-established risk factors for breast cancer. Physical activity was defined as expenditure of energy from recreational physical activity including walking as well as mild, moderate and strenuous physical activity in kcal/week/kg.
Statistical analysis
All demographic and clinical characteristics of women with and without a prior history of statin use at baseline were summarized separately. Separate univariable Cox proportional hazard models were first used to assess the relationship between statin use at baseline and the development of late-stage breast cancer as well as the relationship between statin use at baseline and death due to breast cancer. For the late-stage breast cancer models, women with early-stage breast cancer or those who died during follow-up were censored. Similarly, for models with death due to breast cancer as the primary endpoint, women who died due to other causes were censored. Statin use at baseline was characterized as yes/no, by type (lipophilic/ hydrophilic), and duration of use (\1 year, 1-3 years, 3? years).
Next, to control for potential confounding variables, multivariable models were created using clinically relevant covariates determined a priori: race, education, smoking, BMI, waist circumference, mammogram in the past 2 years, Gail 5-year risk, female relative with breast cancer, age at menarche, number of live births, breast biopsy, hysterectomy, hormone use, oral contraceptive use, aspirin use and study component (hormone trial, dietary modification trial not in hormone trial, and observational study). All covariates in the multivariable models were categorized as shown in Table 1 and included as indicator variables.
The baseline hazard for both the univariable and multivariable models was stratified by age stratum at randomization and WHI trial membership. All two-way interactions with statin use were checked for significance. In addition, the proportional hazard assumption was assessed graphically as well as by including interactions with time (natural log scale); no serious deviations were observed.
To evaluate the effects of change in statin use over time, univariable and multivariable Cox models with statin use (yes/no and by type) as time-dependent exposures, based on updated information on statin intake gathered at followup clinic visits, were next applied to the data. The same covariates from the baseline statin models were used in the time-dependent multivariable models; the baseline hazards were again stratified by age stratum at randomization and WHI trial membership.
Finally, all univariable and multivariable Cox models described above were stratified by ER status (positive vs. negative), and HR and 95 % CI from the baseline statin use, as well as time-dependent statin use, were calculated. All analyses were performed using SAS/STAT software version 9.2 (SAS Institute Inc., Cary, NC), Stata 13 (StataCorp LP, College Station, TX) and R 3.0.2. Table 1 describes the baseline demographic and clinical characteristics of WHI participants stratified by baseline statin use. There were 10,474 (8 %) women who reported statin use at baseline. The mean age of the study cohort was 63.4 years (SD = 7.2 years), and 84.6 % of the study population were white. Statin users were more likely than nonusers to be older, overweight or obese; however, family history of breast cancer, age at menarche, pregnancy history and age at first full-term pregnancy were relatively similar between the statin use groups. Table 2 describes the distribution of statin use at baseline by duration, type of statin used and other statin characteristics. Table 3 shows the relationship between late-stage breast cancer at diagnosis and statin use. In the multivariable model, there was no significant association between statin use at baseline and late-stage breast cancer (HR = 0.93; 95 % CI 0.76-1.14; p = 0.494). In addition, there was no significant relationship between statin use and development of late-stage breast cancer by statin lipophilicity (p = 0.777), duration of use (p = 0.926, data not shown) or statin potency (data not shown). In the multivariable time-dependent analyses, statin use was associated with a modest, but nonsignificant reduction in late-stage breast cancer (HR = 0.84; 95 % CI 0.70-1.02; p = 0.082); however, there was a significantly lower hazard of lateCancer Causes Control (2015) 26:529-539 531 Table 4 shows the relationship between statins and latestage breast cancer stratified by ER status. In the baseline statin use model, there was a nonsignificant trend toward a lower risk of late-stage ER-positive breast cancer among users of statins (HR = 0.85; 95 % CI 0.67-1.08; p = 0.191 from the multivariable model); however, in the time-dependent analysis, there was a significantly lower risk of late-stage ER-positive breast cancer (HR = 0.79; 95 % CI 0.63-0.99; p = 0.044). This association was also seen among women using lipophilic statins compared to nonusers (HR = 0.72; 95 % CI 0.56-0.93; p = 0.012). Table 5 shows the relationship between statins and breast cancer-specific mortality. There were 401 deaths with breast cancer recorded as cause of death, 15,882 other deaths and 112,692 women with no recorded death. In the multivariable model, there was no significant relationship between statin use and breast cancer-specific mortality (HR = 0.91; 95 % CI 0.60-1.37; p = 0.648) and, in addition, no significant relationship between type of statin (p = 0.254) and duration of statin use (p = 0.827, data not shown). In the multivariable time-dependent analysis, statin use (yes vs. no) was associated with a decreased, albeit not statistically significant risk of breast cancer mortality over time (HR = 0.59, 95 % CI 0.32-1.06; p = 0.075). In addition, there was no significant relationship between statin use and breast cancer mortality stratified by ER status (data not shown).
Results
Several sensitivity analyses were performed. First, we checked for possible selection bias by repeating our timevarying multivariable models for late-stage breast cancer without any exclusions for healthcare access; indicator variables for the original inclusion criteria (mammogram in the past 5 years, current health insurance, current healthcare provider and no prior breast cancer) were added as additional covariates in the multivariable models. The hazard ratio for statin use over time (yes vs. no) from the multivariable model using the extended cohort was 0.85 (95 % CI 0.71, 1.01), compared to the original hazard ratio shown in Table 3 of 0.84 (95 % CI 0.84, 1.02). Similarly, the hazard ratios comparing types of statin use over time were extremely similar to the original results (data not shown). Next, multiple imputation using chained equations was performed in order to assess the impact of the missing covariate data (female relative with breast cancer, hysterectomy, oral contraceptive use, aspirin, waist circumference, ethnicity, smoking status, education, BMI, age at menarche, number of live births, breast biopsy and hormone use) for the multivariable late-stage breast cancer models. A total of 17,329/128,676 observations had one or more missing covariate values; imputation using logistic and multinomial logistic models was performed. In addition to the covariates listed above, age, trial membership and outcome were used to fill in missing data. Using 20 imputed datasets, changes to the Cox model HR and CI from the complete case model results were assessed. Again, results from the imputation procedure were similar to our original complete case results (data not shown). Finally, we checked both the univariable and multivariable baseline statin use models using a competing risk approach as described by Fine and Gray [26] . For late-stage breast cancer, early-stage breast cancer and death were treated as competing risks instead of being censored (the 'naïve' models). Similarly, for death due to breast cancer, death due to other causes was treated as a competing risk. For late-stage breast cancer, the differences between the competing risks models and the naïve models were minimal:
The HR for baseline statin use (yes vs. no) from the multivariable competing risks model was 0.93 (95 % CI 0.76-1.14), compared with 0.93 (95 % CI 0.76-1.14) from the naïve model. Similarly, for death due to breast cancer, differences in the hazard ratio and CI for baseline statin use between the multivariable competing risks model (HR = 0.92; 95 % CI 0.62-1.37) and the naïve model (HR = 0.91; 95 % CI 0.60-1.37) were slight. Univariable results for both outcomes between the naïve and competing risks models were also very similar (data not shown).
Discussion
Although prior analysis of data from the WHI revealed no significant relationship between prior statin use and breast cancer incidence [13] , we hypothesized that prior statin use was protective against late-stage breast cancer and breast cancer-specific mortality. Our results revealed no significant relationship between statin use measured at baseline and stage or breast cancer-related mortality; however, when accounting for statin use over time, we found a significantly lower risk of late-stage breast cancer among women who used lipophilic statins, which was even more pronounced for women with ER-positive breast cancer. Furthermore, in the time-dependent analysis, prior statin use was associated with a lower breast cancer-specific mortality, albeit not statistically significant. Anti-invasive properties of statins have been postulated to result from inhibition of farnesyl diphosphate (FFP) and geranylgeranyldipohsphate (GGPP), which are downstream products of the mevalonate pathway and are both involved in posttranslational modification of many proteins [3, 5, [27] [28] [29] . GGPP is involved in geranylgeranylation of rho proteins, which are involved in various cellular functions including gene expression, actin cytoskeleton migration, adhesion and contractility of cells [29] . Thus, by inhibiting the production of GGPP, statins may reduce cell migration and have anti-proliferative and anti-invasive properties. Other potential mechanisms include reduction in nuclear factor kappa B (NFkB) along with rho A inhibition, resulting in a decrease in matrix metalloproteinase 9 (MMP9) and urokinase levels which are important in cell migration [30] as well as inhibition of angiogenesis [31, 32] . Statins can also induce cellular arrest in the G1-to S-phase transition [33] . Finally, reduction in the metastatic potential after treatment with statins has been demonstrated in breast cancer cell lines as well as in mouse models [34, 35] .
While early epidemiologic studies suggest an association between statins and lower breast cancer risk [10-12, 36, 37] , our recent update of data from the WHI showed no significant relationship [13] which has been confirmed in two large meta-analyses [38, 2] . The goal of the current analysis was to evaluate whether prior statin intake is protective against late-stage disease and/or mortality due to breast cancer. Others have evaluated the relationship between statins and breast cancer stage, recurrence risk, and mortality [14] [15] [16] [17] [18] [19] . In a retrospective analysis from the Kaiser Permanente Northern California Cancer Registry, statin use of 1 year or greater before breast cancer diagnosis was associated with a lower risk of ER/PR-negative breast cancer (OR 0.63; 95 % CI 0.43-0.92) and a higher likelihood of low-grade and earlier-stage disease [14] . Use of statins has also been associated with a lower risk of breast cancer recurrence, as in a retrospective cohort of 703 women with stage II or III breast cancer [15] and in a prospective cohort of 1,945 women with stage I-III breast cancer [16] . In a study of 18,769 women with stage I-III breast cancer, lower risk of recurrence [16] was only seen among women with ER-positive breast cancer [17] . Further, in a population-based cohort of 3,024 women with stage I-III breast cancer, lipid-lowering drugs (including statins) were associated with a decreased risk of recurrence (HR = 0.83; 95 % CI 0.54-1.24). Lastly, in a large population-based study in Denmark, statin users compared with nonusers had lower overall cancer mortality rates (HR = 0.85; 95 % CI 0.82-0.87) as well as lower breast cancer-specific mortality (HR = 0.87; 95 % CI 0.79-0.99, p = 0.03) although it is not clear whether the reduction in breast cancer-specific mortality was due to a shift in stage at diagnosis or to other causes [19] . While data on breast cancer recurrence is not available in the WHI, our findings suggest an influence of lipophilic statins on stage at diagnosis among women with ER-sensitive cancers and are consistent with results of another study which showed a lower risk of breast cancer recurrence, also among women with ER-positive disease [16] . The preferential effect of lipophilic statins on breast cancer stage at diagnosis may be due to increased penetration across cellular membranes; however, this finding warrants further investigation. Mendelian randomization designs using genetic variation affecting the cellular uptake of statins could be considered to investigate the causal relationship between statin use and breast cancer staging. Lastly, while the relationship between statins and lower breast cancer mortality was not significant in the WHI analysis, our findings are consistent with those of other reports [15, 17, 18] and again warrant further study. It is possible that our results were not significant in regard to mortality due to the small number of deaths from breast cancer in the WHI. The strengths of this analysis include the comprehensive demographic and cancer risk factor assessment, as well as central review of cancer diagnoses with a long follow-up period and detailed capture of statin use over time by inperson assessment of medication use. Limitations include the low prevalence of statin use at baseline in the WHI compared to current use, and lack of information on medication compliance among study participants. Another limitation is that this was an observational analysis of statins and breast cancer stage, and therefore, baseline riskfactor status, surveillance for breast cancer and other factors that predict either use of statins or diagnosis of breast cancer may have differed between statin users and nonusers. Also, we were not able to use the TNM classification of breast cancer stage due to missing data on the number of affected lymph nodes at the time of diagnosis, and we also excluded 225 women diagnosed with breast cancer due to missing SEER staging which may have had an impact on the power of our study. Other limitations included the relatively modest number of breast cancer deaths and the lack of information on cancer-related treatments.
In conclusion, our results from one of the largest studies to date suggest that lipophilic statins use may reduce the frequency of late stage in favor of earlier-stage breast cancer and may result in lower breast cancer mortality. Further studies should leverage large datasets with longer follow-up and information on specific types of statins used and cancer-directed therapy.
